Advertisement

Topics

Bristol-Myers Squibb Announces Results From Checkmate -143, A Phase III Study Of Opdivo (Nivolumab) In Patients With Glioblastoma Multiforme

20:00 EDT 2 Apr 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Bristol-Myers Squibb Announces Results From Checkmate -143, A Phase III Study Of Opdivo (Nivolumab) In Patients With Glioblastoma Multiforme

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb Announces Results From Checkmate -143, A Phase III Study Of Opdivo (Nivolumab) In Patients With Glioblastoma Multiforme"

Quick Search
Advertisement